WHO: Europe Losing First-Line Antibiotics as Hospital Bacteria Resistance Increases

Doctors across Europe are losing first-line Antibiotic options for serious hospital infections, the World Health Organization warned.

Half or more of tested samples of two common hospital bacteria were drug-resistant in half of European countries involved in research, and the WHO and the European Centre for Disease Prevention and Control are calling for urgent, funded national action.

The warning comes from a joint WHO/Europe and ECDC report built on 2025 laboratory data. In 21 of the 43 countries that reported, at least half of Klebsiella pneumoniae samples were resistant to third-generation cephalosporins — the standard antibiotics doctors reach for first against hospital bloodstream infections. For Acinetobacter, another hospital-dwelling bacterium, the same was true in 21 of 38 reporting countries.

What makes the findings serious is the second line of defence. When cephalosporins fail, clinicians escalate to carbapenems — antibiotics that work against a wider range of bacteria.

Yet resistance to these second-line options is also increasing, with 10 of the reporting countries finding half or more of Klebsiella pneumoniae bacteria resisted carbapenems, and in 21 of 38 countries for Acinetobacter, leaving a shrinking group of last-resort drugs that are often expensive and not available in every country.

“In many countries in our Region, the antibiotics doctors usually reach for first are failing against serious hospital infections. So doctors turn to carbapenems, stronger drugs normally kept for the most serious cases. When those stop working too, what’s left is mostly a small group of last-resort drugs that are often expensive and not available in every country.”

Dr Marc-Alain Widdowson, Programme Manager, Health Security Division, WHO/Europe, tied the resistance directly to survival. He said that matters, because people whose first antibiotic doesn’t work against their infection are more likely to die in hospital.

Drug-resistant superbugs are surging, could send Europe back to a ‘pre-antibiotic era’
Photo: euronews

Antibiotic Resistance Increases Hospital Deaths

  • Antibiotic resistance means bacteria have developed the ability to withstand the drugs designed to kill them or stop their growth — a failed first antibiotic doesn’t just delay treatment, it makes people more likely to die in hospital.
  • The concern here is hospital-associated: Klebsiella pneumoniae and Acinetobacter are common hospital bacteria.
  • WHO/Europe says nearly every country has a plan to tackle antimicrobial resistance, but only 40% report carrying it out with funding in place and regular checks on progress — plans on paper, as Widdowson put it, don’t stop an infection on a hospital ward.

The 2030 Targets Europe Is Missing

The report also grades the EU’s own goals. Two of three targets to reduce bloodstream infections caused by resistant bacteria by 2030 are further from being met than at their starting point in 2019.

Carbapenem-resistant Klebsiella pneumoniae cases rose an estimated 75% between 2019 and 2025 against a target of a 5% fall. The incidence stood at 3.75 cases per 100,000 people, representing a 72% increase compared with the 2019 baseline. Resistant E. coli — the most common cause of bloodstream infections in the EU — rose 16.4% against a target 10% reduction.

One target was met. Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections fell 19% between 2019 and 2025, meeting the target, though rates of infection have risen in the last 2 years, which may put the target at risk.

Measure (EU, 2019–2025) Change 2030 target
Carbapenem-resistant K. pneumoniae bloodstream infections +75% (estimated); incidence 3.75 per 100,000, +72% on baseline −5%
Cephalosporin-resistant E. coli bloodstream infections +16.4% −10%
MRSA bloodstream infections −19% (rising last two years) −15%
Antibiotic consumption in humans −5% −20%
Resistant Acinetobacter bloodstream infections ≈ −50% since 2021 peak —

The Acinetobacter fall is the bright spot: the estimated rate of resistant bloodstream infections has plummeted by almost 50% since the high levels seen in 2021 during the COVID-19 pandemic.

Carbapenem-resistant E. coli infections are being reported not only in healthcare settings but also in the community, and ECDC’s 2026 campaign is focusing on children, who are often exposed to antibiotics. ECDC notes that faster genomic surveillance allows for assessing how resistant bacteria spread and evading antibiotics, helping to act sooner to stop transmission and guide treatment decisions.

Where Resistance Spreads and How It Is Stopped

More than 70% of the health burden of antimicrobial resistance in Europe is attributable to healthcare-associated infections involving multidrug-resistant bacteria — infections caught while hospitalised. ECDC states half of this burden could be prevented through stronger infection prevention and control measures.

Priority measures include reliable hand hygiene, correct use of personal protective equipment, timely identification and isolation of affected patients, and effective environmental cleaning and disinfection. Vaccination can also reduce the need for hospitalisation and antibiotic use overall.

“Without effective antibiotics, we could return to the ‘pre-antibiotic era’, and it would be difficult, if not impossible, to safely perform organ transplantation, cancer chemotherapy, ensure intensive care or other medical procedures,” the ECDC report warned.

ECDC Director Pamela Rendi-Wagner said faster genomic surveillance now shows “how resistant bacteria spread and how they evade antibiotics,” letting health systems “act sooner to stop transmission, more effectively guide treatment decisions, and identify where new antibiotics are most urgently needed.” Between 2024 and 2026, ECDC conducted country visits in all Member States and provided tailored recommendations for AMR and healthcare-associated infections.

What WHO Wants Governments to Fund

WHO/Europe’s asks are concrete: commit money and execute national action plans, with regular checks and reports on progress — only 40% of countries report carrying it out with funding in place and regular checks on progress.

Infection prevention in hospitals should be treated as a priority so that bacteria is unable to spread from patient to patient, allowing opportunity for resistance to grow during treatment. Antibiotics should be used sparingly and as appropriately as possible, keeping carbapenems and last-resort drugs for patients who really need them.

The organisation also calls for investment in laboratories, including national reference laboratories that can identify how bacteria resist carbapenem, as well as collecting more routine blood cultures so doctors will know what will work before providing treatment. Access to last-resort antibiotics should always be available where patients need them.

With many countries still lacking a standardised approach to collecting resistance data and the risk to patients that testing treatments that may not work, the full picture is still unclear.

Community Antibiotic Use Dominates Consumption

90% of all human antibiotic consumption occurs in the community or outpatient sector. Antibiotics should be used sparingly and as appropriately as possible. Because many countries still lack a standardised approach to collecting resistance data, the full picture is still unclear.

The Road Back From Resistance

The trajectory is not uniform — MRSA down 19%, resistant Acinetobacter down almost 50% from 2021, yet carbapenem-resistant Klebsiella up 75%. Cyprus has seen a 716% surge in antibiotic-resistant K. pneumoniae infections, reaching 21.29 cases per 100,000 people last year.

The European Centre for Disease Prevention and Control, the EU agency behind the surveillance data in the report, owes its existence largely to the 2003 SARS outbreak, which confirmed the urgency of an EU-wide public health institution.

Set up in record time for an EU agency — draft legislation in July 2003, regulation passed by spring 2004 — it became operational in May 2005 and is headquartered in Solna, Sweden. One of its seven disease programmes covers antimicrobial resistance and healthcare-associated infections, the very threat now defying the EU’s 2030 targets.

Far fewer have the money and follow-through to make it work, and a plan on paper doesn’t stop an infection on a hospital ward.”

References

  • World Health Organization Regional Office for Europe / European Centre for Disease Prevention and Control — joint report on antimicrobial resistance in the WHO European Region (2025 surveillance data)
  • European Centre for Disease Prevention and Control — Urgent action needed to safeguard the effectiveness of antibiotics
Photo of author

Health Desk

Health Desk at Archyde.

Why Health Insurance Premiums Are Rising: Subsidies, AI, Hospital Power

IHA Survey: At-Home Entertaining Dips Slightly in 2027 as Costs Top Motivations